SYNLAB AG: SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region (news with additional features)
EQS-News: SYNLAB AG / Key word(s): Miscellaneous
SYNLAB Holding Deutschland GmbH
Gubener Straße 39
SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region
SYNLAB, Europe’s leading provider of medical diagnostic services and specialty testing, is further expanding its leading position in southern Germany by investing around 20 million euros in a new, state-of-the-art laboratory location at Schwanthaler Straße 115 in the centre of Munich. Besides the modernisation of the laboratory equipment, SYNLAB also expands its laboratory space at the new location. Thereby, SYNLAB is in a strong position to continue its steady growth path in the region and further expand its leading position. The company has continuously upheld smooth laboratory operations during the relocation and officially inaugurated the new facility at Munich's Theresienwiese in March 2023.
Dr. Olaf Wetlitzky, Medical Director of SYNLAB Labor München Zentrum is very pleased:
“Our core laboratory now has an area of around 6,000 square metres. Having all divisions, including the administration, on one level will significantly improve both the processes in our daily operations as well as the communication among our approximately 200 employees.”
Axel Niedermeyer, Organisational Head of the laboratory, further underlines: “With the relocation, we have upgraded our laboratory to the cutting edge of technology. With our efficient instrumentation, we now achieve a degree of digitalisation of over 70%. As a consequence, we can also further optimise the sample flow. Due to the intense competitive situation in Munich’s laboratory market, this is a real advantage.”
SYNLAB Labor München Zentrum was founded in 1986 and maintains a customer base of over 3,000 medical practices to date. In addition, numerous pharmaceutical and diagnostics companies as well as several private and university clinics benefit from the services of SYNLAB’s experts. The laboratory’s portfolio includes several thousand different tests. 80% of the analyses carried out are completed on the same day.
For more information:
Forward looking statements
This document does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction.
Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believes", "expects”, “expected”, "may", "will", "would", "should", "seeks", "pro forma", "anticipates", "intends", "plans", "estimates", “estimated”, or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results.
09.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
Moosacher Straße 88
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:
End of News
EQS News Service